z-logo
open-access-imgOpen Access
Novel Treatment Targets in Sarcoma: More Than Just the GIST
Author(s) -
Alexander N. Shoushtari,
Brian Andrew Van Tine,
Gary K. Schwartz
Publication year - 2014
Publication title -
american society of clinical oncology educational book
Language(s) - English
Resource type - Journals
eISSN - 1548-8756
pISSN - 1548-8748
DOI - 10.14694/edbook_am.2014.34.e488
Subject(s) - gist , sarcoma , stromal cell , disease , reprogramming , carcinogenesis , cancer research , immunotherapy , medicine , biology , immune system , bioinformatics , pathology , immunology , cancer , cell , genetics
Sarcomas are rare tumors comprising a heterogeneous group of more than 50 histologic subtypes, the majority of which do not respond well to cytotoxic chemotherapy. This has fueled research into the distinct molecular mechanisms of tumorigenesis and disease progression for various sarcoma subtypes. Gastrointestinal stromal tumors and liposarcomas are presented as paradigms of molecular classification that have led to the rational development of novel therapeutic strategies for those tumors. Recent advances in understanding of growth signaling pathways, metabolic reprogramming, and immune therapy have identified new treatment targets for many sarcomas. These investigations will form the foundation for further improvements in our ability to care for patients with these tumors and may offer clinical insights into a wide range of other tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom